[{"id":"17106019-1f09-43d1-b5ca-ce2f02cc6783","acronym":"GLIOSTAR","url":"https://clinicaltrials.gov/study/NCT04573192","created_at":"2023-06-23T01:16:24.218Z","updated_at":"2024-07-02T16:35:10.988Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression","source_id_and_acronym":"NCT04573192 - GLIOSTAR","lead_sponsor":"Philogen S.p.A.","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • Fibromun (onfekafusp alfa)"],"overall_status":"Recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 02/19/2021","start_date":" 02/19/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-08"},{"id":"6f4512bb-8afc-4c34-a25f-189b0c54dc26","acronym":"GLIOASTRA","url":"https://clinicaltrials.gov/study/NCT05304663","created_at":"2022-03-31T17:52:52.829Z","updated_at":"2024-07-02T16:35:10.960Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression","source_id_and_acronym":"NCT05304663 - GLIOASTRA","lead_sponsor":"Philogen S.p.A.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • Fibromun (onfekafusp alfa)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-08"},{"id":"d1c900c0-6be6-4f48-a584-6371c3f163ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT01213732","created_at":"2021-01-18T04:52:19.623Z","updated_at":"2024-07-02T16:36:12.381Z","phase":"Phase 1","brief_title":"Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma","source_id_and_acronym":"NCT01213732","lead_sponsor":"Philogen S.p.A.","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Fibromun (onfekafusp alfa)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 09/01/2011","study_completion_date":" 09/01/2011","last_update_posted":"2022-04-15"},{"id":"8ca2e776-100c-4b44-bd10-c220551b63df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02076620","created_at":"2021-06-03T12:55:06.895Z","updated_at":"2024-07-02T16:36:14.149Z","phase":"Phase 1","brief_title":"L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT02076620","lead_sponsor":"Philogen S.p.A.","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Fibromun (onfekafusp alfa)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 01/16/2013","start_date":" 01/16/2013","primary_txt":" Primary completion: 01/25/2018","primary_completion_date":" 01/25/2018","study_txt":" Completion: 01/25/2018","study_completion_date":" 01/25/2018","last_update_posted":"2022-04-04"}]